

# Evaluation of TNF-alpha Antagonists (Infliximab) Withdrawal in Sarcoidosis

NCT05689879

---

Status	RECRUITING
Phase	Phase 3
Sponsor	Assistance Publique - Hôpitaux de Paris
Enrollment	90 participants

## Key Eligibility Criteria

---

### Inclusion (11)

- Age superior or equal to 18 years
- Clinical and radiological presentation consistent with sarcoidosis
- Presence of non-caseating granulomas in at least one organ
- Exclusion or other causes of granulomas
- Infliximab treatment for at least 6 months

... and 6 more (see full listing online)

### Exclusion (14)

- Pregnancy or breast-feeding
- Positive IGRA (Interferon Gamma Release Assays) test without previous antituberculous antibiotherapy
- Active infection
- Patients with moderate to severe heart failure (NYHA class III/ IV)
- Severe liver function disorders

... and 9 more (see full listing online)

## Locations (1 total)

---

Hôpital de la Pitié-Salpêtrière, Paris, France